EUVIMEDEUVIMED entdecken
Multizentrische Studie

The Anti‐Thyroglobulin Antibody Trajectory and Risk of Structural Recurrence in Patients With Papillary Thyroid Cancer

Hongxi Wang, Tian Tian, Qianrui Li, Rong Tian iD

Head & Neck · 2025

DOI: 10.1002/hed.70109 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Head & Neck, 2025. Verfasst von Hongxi Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Neoplasm Recurrence, Local, Autoantibodies, Thyroid Cancer, Papillary. Die Arbeit nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Department of Sichuan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To explore the relationship between anti‐thyroglobulin antibody (TgAb) trajectories and recurrence risk in papillary thyroid cancer (PTC) patients.

Methods

This multiple‐center, retrospective cohort included 4161 patients who had no evidence of structural disease and a stimulated thyroglobulin (s‐Tg) of ≤ 10 ng/mL at the initial radioiodine (RAI) treatment. Among 3660 patients who had repeated TgAb measurements (before RAI treatment, 1, 6, or 12 months after treatment) and available response assessments, latent class models were used to identify TgAb trajectories. Associations of trajectories with the risk of recurrence were estimated.

Results

Four distinct TgAb trajectories were identified. Compared with patients belonging to the consistently negative trajectory, patients with the other three trajectories had higher risks of recurrence (medium‐level descent: odds ratio = 3.46 [95% CI = 1.56–6.90], high‐level descent: 8.04 [1.26–28.78], persistently increasing: 12.11 [5.73–23.75]).

Conclusions

TgAb trajectories within 1 year after RAI treatment are associated with the risk of recurrence in PTC patients with a s‐Tg ≤ 10 ng/mL. Trial Registration Registered at www.chictr.org.cn (identifier: ChiCTR2300075574)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsNeoplasm Recurrence, LocalAutoantibodiesThyroid Cancer, PapillaryThyroglobulinCarcinoma, PapillaryHumansMaleFemaleRetrospective StudiesMiddle AgedAdultIodine RadioisotopesRisk AssessmentAged

Stichwörter der Autor:innen

antithyroglobulin antibodieslatent class modelpapillary thyroid cancerthyroglobulintreatment response

Substanzen

Autoantibodiesanti-thyroglobulinIodine RadioisotopesThyroglobulin

Autor:innen und Institutionen

  • Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.

ORCID-Profile: Rong Tian

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Department of Sichuan Province

Zitieren

APA

Wang, H., Tian, T., Li, Q., & Tian, R. (2025). The Anti‐Thyroglobulin Antibody Trajectory and Risk of Structural Recurrence in Patients With Papillary Thyroid Cancer. Head & Neck. https://doi.org/10.1002/hed.70109

Vancouver

Wang H, Tian T, Li Q, Tian R. The Anti‐Thyroglobulin Antibody Trajectory and Risk of Structural Recurrence in Patients With Papillary Thyroid Cancer. Head & Neck. 2025. doi:10.1002/hed.70109

BibTeX
@article{Wang2025,
  author = {Wang, Hongxi and Tian, Tian and Li, Qianrui and Tian, Rong},
  title = {The Anti‐Thyroglobulin Antibody Trajectory and Risk of Structural Recurrence in Patients With Papillary Thyroid Cancer},
  journal = {Head & Neck},
  year = {2025},
  doi = {10.1002/hed.70109}
}
Kostenlos starten →